

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Cutia Therapeutics

科笛集团

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2487)

VOLUNTARY ANNOUNCEMENT

INCLUSION OF THE COMPANY AS A CONSTITUENT STOCK OF THE HANG SENG FAMILY OF INDEXES

This announcement is made by Cutia Therapeutics (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board of directors (the “**Board**”) of the Company is pleased to announce that, based on the results of the quarterly review of the Hang Seng Family of Indexes announced by Hang Seng Indexes Company Limited on 18 August 2023, the Company has been selected and will be included as a constituent stock of the following index series, with effect from 4 September 2023:

1. Hang Seng Composite Index;
2. Hang Seng Healthcare Index;
3. Hang Seng Innovative Drug Index;
4. Hang Seng SCHK Innovative Drug Index;
5. Hang Seng SCHK Pharmaceuticals & Biotechnology Index; and
6. Hang Seng SCHK Pharmaceuticals & Biotechnology (Investable) Index.

By being a constituent stock of the Hang Seng Composite Index, the Company has satisfied one of the criteria for being eligible to be included in the southbound trading link of Stock Connect. Further, the Board believes that the Company’s inclusion as a constituent stock of the above index series represents market recognition of the Group’s business performance and development prospects, and is expected to further facilitate the expansion of the Company’s shareholder base and increase trading liquidity of the shares of the Company.

The Board would like to thank the shareholders and investors of the Company for their continuous support. The Company will continue to actively seek market opportunities, strive to develop its business and create value for its shareholders.

By order of the Board

Cutia Therapeutics

Zhang Lele

Chief Executive Officer and Executive Director

Hong Kong, 18 August 2023

As at the date of this announcement, the Board comprises (i) Ms. Zhang Lele and Mr. Huang Yuqing as executive directors; (ii) Dr. Chen Lian Yong, Dr. Xie Qin, Dr. Huang Xiao, Ms. Yang Yunxia as non-executive directors; and (iii) Mr. Chung Ming Kit, Mr. Tao Tak Yan Dennis and Mr. Ye Xiaoxiang as independent non-executive directors.